Integrated transcriptional-phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients.

Darawan RinchaiElena VerzoniVeronica HuberAgata CovaPaola SquarcinaLoris De CeccoFilippo de BraudRaffaele RattaMatteo DugoLuca LalliViviana VallacchiMonica RodolfoJessica RoelandsChiara CastelliDamien ChaussabelGiuseppe ProcopioDavide BedognettiLicia Rivoltini

Published in: Clinical and translational medicine (2022)

The marked but transient nature of this immunomodulation, peaking at the third month of treatment, provides the rationale for the use of antiangiogenics as a preconditioning strategy to improve the efficacy of ICB.

Keyphrases

renal cell carcinoma
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
gene expression
cerebral ischemia
clinical trial
prognostic factors
transcription factor
patient reported outcomes
ischemia reperfusion injury
mesenchymal stem cells
brain injury
drug induced
data analysis